65,437 trials
Superficial Bladder Cancer
Primary: Complete Tumor Response Defined as the Absence of New Tumors — 64.1 percentage of participants
Acne Scarring of the Face
Primary: Evaluator Live Acne Scarring Assessment Responders — 64; 46 Participants — p=0.0109
Metastatic Pancreatic Cancer
Primary: Number of Participants With Dose-limiting Toxicities — 4; 0; 1 participants
Brittle Nails
Primary: Change From Baseline in the Physician's Global Assessment (PGA) of Target Fingernails #1 and #2 — -1.4; -1.4 scores on a scale
HIV Infections · Cardiovascular Disease · Insulin Resistance
Primary: Myocardial Glucose Utilization Rate — 109.6; 106.7; 109.1; 87.2 (nmol glucose/g heart muscle/min
Healthy
Primary: Area Under Curve From 0 to tz Hours (AUC0-tz) of Metformin — 7219.03; 7057.52 ng·h/mL
Type 2 Diabetes Mellitus
Primary: Mean Change From Baseline at Week 16 (95% Confidence Interval) in Glycosated Hemoglobin A1c (HbA1c) (Last Observation Carried Forward) - Full Analysis Set (FAS) — -1.95…
Rheumatoid Arthritis · Psoriatic Arthritis · Ankylosing Spondylitis
Primary: Number of Participants With Adverse Events (AEs) — 171; 116; 47; 115 participants
Photodamaged Skin · Wrinkles
Primary: Global Photodamage Severity — 4.8; 5.45 units on a scale
Haemophilus Influenzae Type b
Primary: Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations Greater Than or Equal to (≥) 0.15 Microgram Per Milliliter (µg/mL) and ≥ 1.0…
Pulmonary Disease, Chronic Obstructive
Primary: Annual Rate of Moderate and Severe COPD Exacerbations Expressed as Least Square Mean — 1.14; 0.92; 0.90; 0.79 Exacerbations per participant per year — p=0.040
Renal Transplanted Recipients
Primary: Calculated Glomerular Filtration Rate (cGFR) After Kidney Transplant to Evaluate Kidney Function (12 Months Analysis) — 65.2; 69.3; 66.9 mL/min per 1.73 m^2
Type 2 Diabetes Mellitus
Primary: Maximum Observed Concentrations (Cmax) of Metformin, Saxagliptin, and 5-Hydroxy (5-OH) Saxagliptin as a Fixed-dose Combination (FDC) and as Individual Tablets — 713…
Non-Small Cell Lung Carcinoma
Primary: Percentage of Participants Who Achieved an Objective Confirmed Complete Response or Partial Response by Blinded Radiology Assessment — 33; 25 percentage of participants…
Asthma
Primary: Number of Participants With Any Adverse Event (AE) or Any Serious Adverse Event (SAE) During the Treatment Period — 6; 9; 0; 0 Participants